caa a22 4500 469119012 CHVBK 20180323133133.0 cr unu---uuuuu 170328e19921001xx s 000 0 eng 10.1007/BF02245477 doi (NATIONALLICENCE)springer-10.1007/BF02245477 Dose-response studies with co-dergocrine mesylate under hypoxia utilizing EEG mapping and psychometry [Elektronische Daten] [Bernd Saletu, Josef Grünberger, Leopold Linzmayer, Peter Anderer] In a double-blind, placebo-controlled trial, human brain function and mental performance were studied under two different degrees of hypoxia after administration of two different doses (6 mg and 9 mg) of co-dergocrine mesylate (CDM) utilizing blood gas analysis, EEG mapping and psychometry. Hypoxic hypoxidosis (i.e. impairment of cerebral metabolism due to hypoxia) was experimentally induced by a fixed gas combination of 9.8% oxygen (O2) and 90.2% nitrogen (N2) (found in 6000 m altitude), and of 8.6% O2, 91.4% N2 (found in 7000 m altitude), which was inhaled for 23 min under normobaric conditions by 18 healthy volunteers. They received randomized after an adaptation session placebo, 6 mg and 9 mg co-dergocrine mesylate (CDM). Evaluation of blood gases, brain mapping and psychometry was carried out at 0, 2, 4, 6, 8 h after oral drug administration. Blood gas analysis demonstrated a drop in PO2 to 42 and 32 mm Hg 23 min after inhalation of the 9.8% and 8.6% gas mixture, respectively, PCO2 decreased to 32 and 31 mm Hg, pH increased to 7.46 and 7.47 and base excess increased to 0.50 and 0.90 nmol/l, respectively. EEG mapping demonstrated an increase in delta and decrease of alpha power and a slowing of the centroid over almost the whole brain. 6 mg and slightly less so 9 mg CDM attenuated this deterioration of vigilance (i.e. dynamic state of the neuronal network determining adaptive behavior). At the behavioral level, moderate hypoxia induced a deterioration of noopsychic performance, which was mitigated by 6 mg, but not by 9 mg CDM. A deepening of the hypoxia resulted in a loss of these brain protective effects of both doses. Decrement of the thymopsyche increased after both doses in the moderate hypoxic condition, while under marked hypoxia 6 mg CDM attenuated and 9 mg aggravated this deterioration. Time-wise, brain protective effects reached the level of statistical difference between the 2nd and the 6th hour. Somatic complaints like feeling dazed, giddiness and headache were mitigated dose dependently by CDM in the moderate, but not in the marked hypoxic hypoxidosis. Springer-Verlag, 1992 Cerebral hypoxic hypoxidosis nationallicence Brain protection nationallicence Blood gases nationallicence EEG mapping nationallicence Psychometry nationallicence Co-dergocrine mesylate nationallicence Gerontopsychopharmacology nationallicence Nootropics nationallicence Saletu Bernd Department of Psychiatry, School of Medicine, University of Vienna, Währinger Gürtel 18-20, A-1090, Vienna, Austria aut Grünberger Josef Department of Psychiatry, School of Medicine, University of Vienna, Währinger Gürtel 18-20, A-1090, Vienna, Austria aut Linzmayer Leopold Department of Psychiatry, School of Medicine, University of Vienna, Währinger Gürtel 18-20, A-1090, Vienna, Austria aut Anderer Peter Department of Psychiatry, School of Medicine, University of Vienna, Währinger Gürtel 18-20, A-1090, Vienna, Austria aut Psychopharmacology Springer-Verlag 109/1-2(1992-10-01), 30-40 0033-3158 109:1-2<30 1992 109 213 https://doi.org/10.1007/BF02245477 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF02245477 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Saletu Bernd Department of Psychiatry, School of Medicine, University of Vienna, Währinger Gürtel 18-20, A-1090, Vienna, Austria aut NATIONALLICENCE 700 1- Grünberger Josef Department of Psychiatry, School of Medicine, University of Vienna, Währinger Gürtel 18-20, A-1090, Vienna, Austria aut NATIONALLICENCE 700 1- Linzmayer Leopold Department of Psychiatry, School of Medicine, University of Vienna, Währinger Gürtel 18-20, A-1090, Vienna, Austria aut NATIONALLICENCE 700 1- Anderer Peter Department of Psychiatry, School of Medicine, University of Vienna, Währinger Gürtel 18-20, A-1090, Vienna, Austria aut NATIONALLICENCE 773 0- Psychopharmacology Springer-Verlag 109/1-2(1992-10-01), 30-40 0033-3158 109:1-2<30 1992 109 213 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer